Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) ·
Feosol, Fer-In-Sol, Slow Fe; mostly generic and OTC (1) ·
Folvite; mostly generic (1) ·
Many generics/OTC (1) ·
Many OTC and Rx; Nascobal (intranasal); generic injection (1) ·
Mucinex, Robitussin, Tussin (1) ·
Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL) (1)
classes:
APL)]] (1) ·
[[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]] (1) ·
[[:Category:Antineoplastics|Antineoplastic (oral (1) ·
[[:Category:Antineoplastics|Antineoplastic]] (1) ·
[[:Category:B-vitamins|B-vitamin]] (3) ·
[[:Category:Expectorants|Expectorant]] (1) ·
[[:Category:Hematinics|Hematinic]] (3) ·
[[:Category:Iron_supplements|Iron supplement]] (1) ·
[[:Category:Mucolytics|Mucolytic]] (1) ·
[[:Category:Retinoids|Retinoid]] (1) ·
[[:Category:Topical_retinoids|Topical retinoid]] (1) ·
[[:Category:Vitamins|Vitamin]] (3)
mechanism:
None (5) ·
'"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1) ·
'"`UNIQ--vote-0000124C-QINU`"' The 400 mg/d dose for migraine prophylaxis is supported by randomized trials (Schoenen 1998) and remains a low-risk evidence-based supplement option. Characteristic bright-yellow urine fluorescence with high-dose oral supplementation. (1)
uses:
'"`UNIQ--vote-0000059A-QINU`"', '"`UNIQ--vote-0000059B-QINU`"' (1) ·
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"' (1) ·
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"' (1) ·
'"`UNIQ--vote-00000BA0-QINU`"', '"`UNIQ--vote-00000BA1-QINU`"', '"`UNIQ--vote-00000BA2-QINU`"' (1) ·
'"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"' (1) ·
'"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"' (1) ·
'"`UNIQ--vote-0000124D-QINU`"', '"`UNIQ--vote-0000124E-QINU`"', '"`UNIQ--vote-0000124F-QINU`"' (1)
starting dose:
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) ·
200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) ·
325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden (1) ·
Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d (1) ·
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1) ·
Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1) ·
Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1)
preparations:
0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection (1) ·
0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) ·
100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) ·
100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual (1) ·
25, 50, 100, 250, 400 mg tablets; OTC (1) ·
325 mg tablets (65 mg elemental Fe); 220 mg/5 mL liquid (44 mg elemental Fe/5 mL); 142 mg/mL drops; OTC and Rx (1) ·
Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid) (1)
fda max:
1 mg/d typical Rx; higher in specific indications (1) ·
2.4 g/d (1) ·
No strict ceiling for water-soluble vitamin; UL not set (1) ·
No strict ceiling; water-soluble vitamin, low toxicity (1) ·
Topical: nightly; oral APL: 45 mg/m²/d (1) ·
Topical: nightly; systemic: regimen-specific (1) ·
~200 mg elemental iron/d typical practical limit (1)
routes:
onset:
30 minutes (1) ·
Hematologic response within days (1) ·
Migraine effect after 1-3 months of daily use (1) ·
Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1) ·
Reticulocyte response at 7-10 days; hemoglobin rise of ~1 g/dL per 3 weeks (1) ·
Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) ·
Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1)
duration: (Click arrow to add another value)
halflife:
N/A (incorporated into hemoglobin and tissue stores) (1) ·
~0.5 hours plasma; tissue retention longer (1) ·
~0.5-2 hours (oral)'"`UNIQ--ref-00000BA3-QINU`"' (1) ·
~1 hour'"`UNIQ--ref-00001050-QINU`"' (1) ·
~1-2 hours plasma (riboflavin itself); FAD/FMN tissue cofactors are continuous (1) ·
~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' (1) ·
~6 days (plasma); hepatic stores last 3-5 years (1)
bioavailability:
10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate) (1) ·
High (oral) (1) ·
High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) ·
Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100% (1) ·
Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) ·
Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) ·
~50-60% (oral; food enhances) (1)
pregnancy:
None (1) ·
Generally considered acceptable.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in pregnancy and preconception to prevent neural tube defects.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in vegan pregnancies and pernicious anemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely used; iron requirements rise substantially in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Safe at replacement and supplement doses.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 7 results in range #1 to #7.